Fluorescence Cystoscopy in the Management of Bladder Cancer: A Help for the Urologist!Jichlinski P. · Leisinger H.-J.
Department of Urology, CHUV, Lausanne, Switzerland
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
As a disease characterized by a nature polymorphic and fluctuant in its evolution, superficial transitional cell carcinoma of the bladder remains a perpetual therapeutic challenge, and raises a great interest in the development of new diagnostic and surveillance techniques. This paper reviews 10 years of experience of fluorescence cystoscopy, a simple technique perfectly adapted to the current endoscopic equipment. Its principle is to enhance the visual contrast between benign and malignant cells. Three photosensitizing agents are available, two prodrugs: δ-aminolevulinic acid or hexaminolevulinate, and a natural substance: hypericin. With a detection rate of over 90% for carcinoma in situ and a real potential for detecting small tumors overlooked by standard cystoscopy, fluorescence cystoscopy may be clearly recommended in clinical practice. This technique favors a standardization of superficial bladder cancer endoscopic management and is susceptible to have a real impact on the disease recurrence and progression rate.
© 2005 S. Karger AG, Basel
- Borden LS, Clark PE, Hall MC: Bladder cancer. Curr Opin Oncol 2003;15:227–233.
- Kurt KH, Bouffioux C, Sylvester R, van den Meijden APM, Oosterlinck W, Brausi M, the EORTC Genitourinary Group: Treatment of superficial bladder tumors: Achievement and needs. Eur Urol 2000;37(suppl 3):1–9.
- Jakse G, Algaba F, Malmström PU, Oosterlink W: A second-look TUR in T1 transitional cell carcinoma: Why? Eur Urol 2004;45:539–546.
- Jichlinski P: New diagnostic strategies in the detection and staging of bladder cancer. Curr Opin Urol 2003;13:351–355.
Kriegmair M, Baumgartner R, Hofstetter A: Intravesikale Instillation von δ-Aminolävulinsäure (ALA) – Eine neue Methode zur photodynamischen Diagnostik und Therapie. Lasermedizin 1992;8S:83.
- Vicente J, Chècile G, Algaba F: Value of in vivo mucosa-staining test with methylene blue in the diagnosis of pretumoral and tumoral lesions of the bladder. Eur Urol 1987;13:15–16.
- Jocham D, Baumgartner R, Fuchs N, Lenz H, Stepp H, Unsöld E: Die Fluoreszenzdiagnose Porphyrin-markierter urothelialer Tumoren. Urologe A 1989;28:59–64.
- Kennedy JC, Pottier RH, Pross DC: Photodynamic therapy with endogenous protoporphyrin IX: Basic principles and present clinical experience. J PhotochemPhotobiol B 1990;6:143–148.
- Kriegmair M, Baumgartner R, Knuechel R, Steinbach P, Ehsan A, Lumper W, Hofstadter F, Hofstetter A: Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology 1994;44:836–841.
- Jichlinski P, Forrer M, Mizeret J, Glanzmann T, Braichotte D, Wagnières G, Zimmer G, Guillou L, Schmidlin F, Graber P, van den Bergh H, Leisinger HJ: Clinical evaluation of a method for detecting superficial transitional cell carcinoma of the bladder by light induced fluorescence of protoporphyrin IX following topical application of 5-aminolevulinic acid. Preliminary results. Lasers Surg Med 1997;20:402–408.
- Koenig F, McGovern FJ, Larne R, Enquist H, Schomacker KT, Deutsch TF: Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid. BJU Int 1999;83:129–135.
- Zaak D, Kriegmair M, Stepp H, Stepp H, Baumgartner R, Oberneder R, Schneede P, Corvin S, Frimberger D, Knuchel R, Hofstetter A: Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: Results of 1,012 fluorescence endoscopies. Urology 2001;57:690–694.
- Lange N, Jichlinski P, Zellweger M, Forrer M, Marti A, Guillou L, Kucera P, Wagnières G, van den Bergh H: Photodetection of early human bladder cancer based on the fluorescence of 5-aminolevulinic acid hexylester-induced protoporphyrin IX: A pilot study. Br J Cancer 1999;80:185–193.
- Jichlinski P, Guillou L, Karlsen SJ, Malmstrom PU, Jocham D, Brennhovd B, Johansson E, Gartner T, Lange N, van den Bergh H, Leisinger HJ: Hexyl aminolevulinate fluorescence cystoscopy: New diagnostic tool for photodiagnosis of superficial bladder cancer – A multicenter study. J Urol 2003;170:226–229.
- D’Hallewin MA, De Witte P, Waelkens E, Merlevede W, Baert L: Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin. J Urol 2000;164:349–351.
- D’Hallewin MA, Kamuhabwa AR, Roskams T, de Witte PA, Baert L: Hypericin-based fluorescence diagnosis of bladder carcinoma. BJU 2002;89:760–763.
- Krieg RC, Fickweiler S, Wolfbeis OS, Knuechel R: Cell-type specific protoporphyrin IX metabolism in human bladder cancer in vitro. Photochem Photobiol 2000;72:226–233.
- Rathert P: Urinzytologie beim Harnblasenkarzinom-Kritische Wertung. Urologe A 2003;42:908–911.
- D’Hallewin MA, Bezdetnaya L, Guillemin F: Fluorescence detection of bladder cancer: A review. Eur Urol 2002;42:417–425.
- Schneeweiss S, Kriegmair M, Stepp H: Is everything all right if nothing seems wrong? A simple method of assessing the diagnostic value of endoscopic procedures when a gold standard is absent. J Urol 1999;161:1116–1119.
- Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M, Hexvix PCB301/01 Study Group: Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004;171:135–138.
Gomella LG, Grossman HB, Presti JC, Lerner SP, Cookson MS, Albala DM, Nseyo UO, Fradet Y, Bihrle R, Fuchs GJ, Morales A, Chad WMR, Droller MJ: The use of Hexvix and fluorescence cystoscopy as an adjunct in the diagnosis of carcinoma in situ of the urinary bladder. J Urol 2004;171:264A
- Theodorescu D: Molecular pathogenesis of urothelial bladder cancer. Histol Histopathol 2003;18:259–274.
- Filbeck T, Roessler W, Knuechel R, Straub M, Kiel HJ, Wieland WF: 5-Aminolevulinic acid induced fluorescence endoscopy applied after conventional resection of primary superficial bladder tumors. Urology 1999;53:77–81.
- Grimbergen MC, van Swol CF, Jonges TG, Boon TA, van Moorselaar RJ: Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. Eur Urol 2003;44:51–56.
- Zaak D, Frimberger D, Stepp H, Wagner S, Baumgartner R, Schneede P, Siebels M, Knuchel R, Kriegmair M, Hofstetter A: Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection. J Urol 2001;166:1665–1668.
- Zaak D, Stepp H, Baumgartner R, Schneede P, Waidelich R, Frimberger D, Hartmann A, Kunchel R, Hofstetter A, Hohla A: Ultraviolet-excited (308 nm) autofluorescence for bladder cancer detection. Urology 2002;60:1029–1033.
- Kriegmair M, Zaak D, Rothenberger KH, Rassweiler J, Jocham D, Eisenberger F, Tauber R, Stenzl A, Hofstetter A: Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 2002;168:475–478.
- Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W: Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol 2002;168:67–71.
Grossman HB, Gomella LG, Fradet Y, Presti JC, Chad WMR, Lerner SP, Cookson MS, Nseyo UO, Bihrle R, Fuchs GJ, Schoenberg MP, Droller MJ: The use of Hexvix and fluorescence cystoscopy as an adjunct in the diagnosis of stage TA/T1 urothelial cancer in the urinary bladder. J Urol 2004;171:263A.
Durek C, Wagner S, Zeylemaker B, Van Moorselaar J, Witjes F, Grimm MO, Muschter R, Popken G, König F, Kurth KH, Knüchel-Clarke R, Jocham D: The significance of hexyl 5-aminolevulinate hydrochloride-based fluorescence cystoscopy in treatment decisions – Results of a prospective phase 3 multicenter study. Eur Urol 2004;3:369A.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.